FDA Brief

Warning letters Drugs

FDA warning letter to

Columbia Cosmetics Manufacturing Inc.

High riskIssued Sep 11, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.

What happened

FDA inspected Columbia Cosmetics Manufacturing Inc.'s drug manufacturing facility from April 7 to 14, 2025. FDA found significant CGMP violations for OTC sunscreen drug products, including inadequate out-of-specification investigations, release of subpotent product, missing identity testing for high-risk components such as glycerin, and unvalidated manufacturing processes. FDA also said the firm's quality system was ineffective.

What FDA found

  1. The firm did not thoroughly investigate out-of-specification results and released subpotent sunscreen drug product without adequate quality group review.

    21 CFR 211.192
  2. The firm did not perform adequate identity testing on each incoming component lot, including glycerin at risk for diethylene glycol or ethylene glycol contamination, and did not establish the reliability of supplier certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The firm manufactured OTC sunscreen drug products without adequate validation of its manufacturing processes.

    21 CFR 211.100(a)
  4. The firm's quality group was not enabled to exercise proper authority or did not sufficiently implement its responsibilities.

    21 CFR parts 210 and 211

What FDA wants

FDA asks Columbia to correct the violations promptly and respond in writing within 15 working days with corrective actions, including a retrospective out-of-specification review, diethylene glycol/ethylene glycol testing and risk assessment, process validation, and quality-system remediation. FDA also recommends a qualified current good manufacturing practice consultant.

Who should pay attention

  • brands that buy OTC sunscreens from this contract manufacturer
  • companies relying on supplier certificates of analysis for high-risk ingredients
  • contract manufacturers making OTC drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk